8-K: Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer

Pacira BioSciences has appointed Shawn Cross as its new Chief Financial Officer, effective October 21, 2024.

Summary

• Pacira BioSciences has appointed Shawn M. Cross as Chief Financial Officer, effective October 21, 2024.
• Mr. Cross succeeds Lauren Riker, who served as interim CFO since October 1, 2024, and will continue as Senior Vice President of Finance.
• Mr. Cross has over 25 years of experience in the biopharmaceutical industry, including roles at Applied Molecular Transport, JMP Securities, and Deutsche Bank.
• His compensation includes an annual base salary of $525,000, a 50% annual incentive bonus target, and participation in a long-term incentive plan.
• He will also receive an initial equity grant of 200,000 nonqualified stock options and 75,000 restricted stock units.
• The stock options vest over four years, and the restricted stock units vest over four years, both subject to continued service.
• Mr. Cross is entitled to certain severance benefits if terminated without cause or if he terminates for good reason, especially within a change of control period.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the appointment of an experienced CFO and the company's strong financial position. The language used is optimistic about future growth and value creation.

Positives

• Pacira has secured an experienced CFO with over 25 years in the biopharmaceutical and investment banking sectors.
• Mr. Cross has a proven track record, including leading a company through an IPO and a merger.
• The compensation package includes a base salary, bonus potential, and equity grants, aligning his interests with the company's success.
• The company is on strong financial footing with a business that is generating significant cash flow driven by three best-in-class, market-leading products.

Negatives

• The document does not explicitly mention any negative aspects of the appointment or the company's current situation.

Risks

• The document mentions risks related to the integration of new executives, which could impact the company's performance.
• There are general risks associated with acquisitions, manufacturing, supply chain, and economic conditions that could affect the company.
• The success of the company's products and their market acceptance are also listed as potential risks.
• The company's future performance is subject to various factors, including clinical trial outcomes and regulatory approvals.

Future Outlook

The company anticipates continued growth and value creation, with a focus on resource allocation and execution. They plan to invest in the next phase of growth and beyond, leveraging their strong financial position and market-leading products. The company is also advancing the development of PCRX-201, a novel locally administered gene therapy.

Management Comments

• Frank D. Lee, chief executive officer of Pacira BioSciences, stated that they are delighted to welcome Shawn as their new Chief Financial Officer and look forward to his leadership and guidance.
• Shawn Cross stated that he is proud to join Pacira as he is strongly aligned with the company's mission to deliver innovative, non-opioid pain therapies.

Industry Context

This announcement is consistent with the trend of biopharmaceutical companies strengthening their leadership teams with experienced financial executives. Mr. Cross's background in investment banking and previous executive roles in the sector aligns with Pacira's growth strategy and focus on financial stability and expansion.

Comparison to Industry Standards

• The compensation package for Mr. Cross, including a base salary, bonus, and equity grants, is typical for a CFO role in a publicly traded biopharmaceutical company.
• His previous experience at Applied Molecular Transport, a company focused on novel therapeutics, is comparable to Pacira's focus on innovative pain therapies.
• The vesting schedules for stock options and restricted stock units are standard practice in the industry, designed to incentivize long-term performance and retention.
• The severance terms are also typical for executive employment agreements, providing protection in case of termination without cause or a change of control.

Management Changes

Stakeholder Impact

• Shareholders may view the appointment of an experienced CFO positively, potentially increasing investor confidence.
• Employees may be impacted by the new leadership, but the document does not suggest any negative changes.
• Customers and suppliers are unlikely to be directly impacted by this executive appointment.

Next Steps

• Mr. Cross will assume his role as CFO on October 21, 2024.
• The company will file the full Employment Agreement as an exhibit to its Annual Report on Form 10-K for the year ended December 31, 2024.
• The stock options will be granted on November 4, 2024, with the exercise price set based on the closing price of the company's common stock on that date.

Key Dates

Keywords

Chief Financial Officer, CFO, Pacira BioSciences, Shawn Cross, Executive Appointment, Biopharmaceutical, Stock Options, Restricted Stock Units, Compensation, Inducement Awards